No clear answer
Dapirolizumab pegol: reduce relapses and new lesions in relapsing MS
relapsing MS · T-cell co-stimulation / cytokine targeting
Trials have tried this, but none was a controlled phase 2 or 3 trial with a readable result.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 0
- People in controlled trials
- 0
No controlled trial has reported a result yet.
Other linked trials: 1
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Other linked trials: 1
These linked trials do not set the status.
- Efficacy and Safety Study of Dapirolizumab pegol (BIIB133) in Participants with RMSStopped, other reason
Phase 2 · 2020 · Compared with ocrelizumab
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-27First listed as No clear answer
Related hypotheses
- Laquinimod: protect nerve tissue in relapsing MS
- Laquinimod: slow disability worsening in relapsing MS
- Abatacept: reduce relapses and new lesions in relapsing MS
- Daclizumab: reduce relapses and new lesions in relapsing MS
- Frexalimab: reduce relapses and new lesions in relapsing MS
- Laquinimod: reduce relapses and new lesions in relapsing MS
- Secukinumab: reduce relapses and new lesions in relapsing MS
- Ustekinumab: reduce relapses and new lesions in relapsing MS
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error